Mirus to Study Gene Silencing for Pfizer | GenomeWeb
NEW YORK (GenomeWeb News) — Mirus Bio yesterday said it has signed a two-year, “multi-million dollar” deal with Pfizer to target and suppress the expression of certain genes.
 
Under the deal, Mirus said it will study methods for optimizing gene silencing methods in animals.
 
Mirus said the agreement will help it speed development of delivery methods for its RNAi technology.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.